• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

FibroScan-AST评分与肝脏硬度对丙型肝炎病毒治愈后肝脏事件的预测作用

FibroScan-AST Score vs Liver Stiffness for the Prediction of Liver Events After HCV Cure.

作者信息

Corma-Gómez Anaïs, Corona-Mata Diana, Martín-Carmona Jésica, Galindo María José, Camacho Angela, Martín-Sierra Carmen, Gallo-Marín Marina, Rincón Pilar, Perez-Valero Ignacio, Pérez-García Margarita, Carrasco-Dorado Angela, Pineda Juan A, Rivero-Juárez Antonio, Rivero Antonio, Real Luis M, Macías Juan

机构信息

Grupo de Virología Clínica e ITS Cinical Virology and STIs Group, Unit of Infectious Diseases and Microbiology, de Hospital Universitario Virgen de Valme, Sevilla, Spain.

Instituto de Biomedicina de Sevilla (IBiS)/CSIC, Sevilla, Spain.

出版信息

Open Forum Infect Dis. 2025 Apr 8;12(4):ofae628. doi: 10.1093/ofid/ofae628. eCollection 2025 Apr.

DOI:10.1093/ofid/ofae628
PMID:40201720
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11977108/
Abstract

BACKGROUND

Liver stiffness (LS) predicts liver complication occurrence in patients with hepatitis C virus (HCV) infection after sustained virological response (SVR). The FibroScan-AST (FAST) score, which includes aspartate aminotransferase (AST) and controlled attenuation parameter (CAP; measured by FibroScan), may improve the prediction ability of isolated LS. Our aim was to compare the predictive capacity of LS vs FAST in this setting.

METHODS

Multicenter cohort study including individuals with HIV/HCV coinfection or HCV monoinfection from Spain if they had (1) LS ≥9.5 kPa pretreatment, (2) SVR with a direct-acting antiviral (DAA)-based regimen, and (3) LS and CAP measurement at SVR. Fatty liver disease (FLD) was defined as CAP ≥248 dB/m. The primary outcome was the occurrence of a liver complication (decompensation or hepatocellular carcinoma [HCC]) after SVR.

RESULTS

Three hundred patients were included; 213 (71%) had HIV. At SVR, 131 (44%) had FLD. The FAST score was <0.35 in 182 (61%), 0.35-0.67 in 79 (27%), and >0.67 in 34 (12%) patients. After a median (Q1-Q3) follow-up of 73 (53-83) months, 36 (12%) liver complications (15 [5%] HCC) occurred. LS was independently associated with an increased risk of developing liver complications (sub-hazard ratio [sHR], 1.06; 95% CI, 1.04-1.08; < .001). In a separate model, FAST ≥0.35 was also independently associated with greater risk of liver complications (sHR, 8.12; 95% CI, 3.11-21.17; < .001). The area under the receiver operating characteristics curve of the model based on LS was 0.83 (95% CI, 0.76-0.91), and that of the model based on FAST was 0.80 (95% CI, 0.72-0.88; = .158).

CONCLUSIONS

The FAST score predicts the development of liver events after SVR but does not improve the predictive capacity of LS alone at this time point.

摘要

背景

肝硬度(LS)可预测丙型肝炎病毒(HCV)感染患者在持续病毒学应答(SVR)后发生肝脏并发症的情况。FibroScan-天门冬氨酸氨基转移酶(AST)(FAST)评分,包括天门冬氨酸氨基转移酶(AST)和受控衰减参数(CAP;通过FibroScan测量),可能会提高单独LS的预测能力。我们的目的是比较在这种情况下LS与FAST的预测能力。

方法

多中心队列研究,纳入来自西班牙的HIV/HCV合并感染或HCV单一感染个体,条件为:(1)治疗前LS≥9.5 kPa;(2)基于直接抗病毒药物(DAA)方案实现SVR;(3)在SVR时测量LS和CAP。脂肪肝疾病(FLD)定义为CAP≥248 dB/m。主要结局是SVR后发生肝脏并发症(失代偿或肝细胞癌[HCC])。

结果

共纳入300例患者;213例(71%)合并HIV。在SVR时,131例(44%)有FLD。182例(61%)患者的FAST评分<0.35,79例(27%)为0.35 - 0.67,34例(12%)>0.67。在中位(四分位间距)随访73(53 - 83)个月后,发生36例(12%)肝脏并发症(15例[5%] HCC)。LS与发生肝脏并发症的风险增加独立相关(亚风险比[sHR],1.06;95%置信区间[CI],1.04 - 1.08;P <.001)。在另一个模型中,FAST≥0.35也与肝脏并发症风险增加独立相关(sHR,8.12;95% CI,3.11 - 21.17;P <.001)。基于LS的模型的受试者工作特征曲线下面积为0.83(95% CI,0.76 - 0.91),基于FAST的模型的受试者工作特征曲线下面积为0.80(95% CI,0.72 - 0.88;P =.158)。

结论

FAST评分可预测SVR后肝脏事件的发生,但在该时间点并不能单独提高LS的预测能力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5881/11977108/606d04b1edf3/ofae628f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5881/11977108/0ce8e24be58a/ofae628f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5881/11977108/606d04b1edf3/ofae628f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5881/11977108/0ce8e24be58a/ofae628f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5881/11977108/606d04b1edf3/ofae628f2.jpg

相似文献

1
FibroScan-AST Score vs Liver Stiffness for the Prediction of Liver Events After HCV Cure.FibroScan-AST评分与肝脏硬度对丙型肝炎病毒治愈后肝脏事件的预测作用
Open Forum Infect Dis. 2025 Apr 8;12(4):ofae628. doi: 10.1093/ofid/ofae628. eCollection 2025 Apr.
2
Liver Stiffness at the Time of Sustained Virological Response Predicts the Clinical Outcome in People Living With Human Immunodeficiency Virus and Hepatitis C Virus With Advanced Fibrosis Treated With Direct-acting Antivirals.在直接作用抗病毒药物治疗下,患有晚期纤维化的人类免疫缺陷病毒和丙型肝炎病毒感染者,在持续病毒学应答时的肝硬度可预测临床结局。
Clin Infect Dis. 2020 Dec 3;71(9):2354-2362. doi: 10.1093/cid/ciz1140.
3
Human Immunodeficiency Virus (HIV) Infection Is Associated With Lower Risk of Hepatocellular Carcinoma After Sustained Virological Response to Direct-acting Antivirals in Hepatitis C Infected Patients With Advanced Fibrosis.在丙型肝炎感染且伴有严重肝纤维化的患者中,对直接抗病毒药物产生持续病毒学应答后,人类免疫缺陷病毒(HIV)感染与肝细胞癌风险降低相关。
Clin Infect Dis. 2021 Oct 5;73(7):e2109-e2116. doi: 10.1093/cid/ciaa1111.
4
No Impact of HIV Coinfection on Mortality in Patients With Hepatitis C Virus Infection After Sustained Virological Response.丙型肝炎病毒感染患者实现持续病毒学应答后,合并感染人类免疫缺陷病毒对死亡率无影响。
Clin Infect Dis. 2025 Apr 30;80(4):835-841. doi: 10.1093/cid/ciae473.
5
Association between Liver Stiffness and Liver-Related Events in HCV-Infected Patients after Successful Treatment with Direct-Acting Antivirals.直接作用抗病毒药物治疗后 HCV 感染患者肝硬度与肝脏相关事件的相关性。
Medicina (Kaunas). 2023 Mar 18;59(3):602. doi: 10.3390/medicina59030602.
6
Liver Stiffness-Based Strategies Predict Absence of Variceal Bleeding in Cirrhotic Hepatitis C Virus-Infected Patients With and Without Human Immunodeficiency Virus Coinfection After Sustained Virological Response.基于肝硬度的策略预测 HCV 肝硬化合并 HIV 感染患者获得持续病毒学应答后是否发生静脉曲张出血。
Clin Infect Dis. 2021 Mar 1;72(5):e96-e102. doi: 10.1093/cid/ciaa1726.
7
HIV infection does not increase the risk of liver complications in hepatitis C virus-infected patient with advanced fibrosis, after sustained virological response with direct-acting antivirals.HIV 感染不会增加 ADV 治疗后 HCV 感染伴有晚期纤维化患者的肝脏并发症风险。
AIDS. 2019 Jun 1;33(7):1167-1174. doi: 10.1097/QAD.0000000000002186.
8
Kinetics of emergence of liver complications in hepatitis C virus infected patients and advanced fibrosis, with and without HIV-coinfection, after sustained virological response.慢性丙型肝炎病毒感染者在获得持续病毒学应答后发生肝脏并发症和肝纤维化进展的动力学:有无 HIV 合并感染的差异。
AIDS. 2021 Nov 1;35(13):2119-2127. doi: 10.1097/QAD.0000000000002959.
9
Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals.口服抗病毒药物治疗后,丙型肝炎相关代偿性晚期慢性肝病患者肝脏相关事件的无创预测。
J Hepatol. 2020 Mar;72(3):472-480. doi: 10.1016/j.jhep.2019.10.005. Epub 2019 Oct 17.
10
Regression of liver stiffness after sustained hepatitis C virus (HCV) virological responses among HIV/HCV-coinfected patients.HIV/丙型肝炎病毒(HCV)合并感染患者持续丙肝病毒(HCV)病毒学应答后肝脏硬度的消退情况
AIDS. 2015 Sep 10;29(14):1821-30. doi: 10.1097/QAD.0000000000000787.

本文引用的文献

1
Predicting fibrosis progression in non-alcoholic fatty liver disease patients using the FAST Score: A paired biopsy study.使用FAST评分预测非酒精性脂肪性肝病患者的纤维化进展:一项配对活检研究。
Hepatol Forum. 2024 Jan 16;5(1):33-36. doi: 10.14744/hf.2023.2023.0021. eCollection 2024.
2
Pathobiology of Metabolic-Associated Fatty Liver Disease.代谢相关性脂肪性肝病的病理生物学
Endocrinol Metab Clin North Am. 2023 Sep;52(3):405-416. doi: 10.1016/j.ecl.2023.01.001. Epub 2023 Mar 8.
3
Global burden of liver disease: 2023 update.全球肝病负担:2023 年更新。
J Hepatol. 2023 Aug;79(2):516-537. doi: 10.1016/j.jhep.2023.03.017. Epub 2023 Mar 27.
4
The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review.非酒精性脂肪性肝病(NAFLD)和非酒精性脂肪性肝炎(NASH)的全球流行病学:系统评价。
Hepatology. 2023 Apr 1;77(4):1335-1347. doi: 10.1097/HEP.0000000000000004. Epub 2023 Jan 3.
5
Diagnostic accuracy of FibroScan-AST (FAST) score for the non-invasive identification of patients with fibrotic non-alcoholic steatohepatitis: a systematic review and meta-analysis.FibroScan-AST(FAST)评分对纤维化非酒精性脂肪性肝炎患者非侵入性识别的诊断准确性:系统评价和荟萃分析。
Gut. 2023 Jul;72(7):1399-1409. doi: 10.1136/gutjnl-2022-328689. Epub 2023 Jan 4.
6
Fib-4 index predicts prognosis after achievement of sustained virologic response following direct-acting antiviral treatment in patients with hepatitis C virus infection.Fib-4指数可预测丙型肝炎病毒感染患者在接受直接抗病毒治疗后实现持续病毒学应答后的预后。
Eur J Gastroenterol Hepatol. 2023 Feb 1;35(2):219-226. doi: 10.1097/MEG.0000000000002479. Epub 2022 Nov 29.
7
Improvement of liver fibrosis, but not steatosis, after HCV eradication as assessment by MR-based imaging: Role of metabolic derangement and host genetic variants.基于磁共振成像评估 HCV 清除后肝纤维化的改善,但非脂肪变性:代谢紊乱和宿主遗传变异的作用。
PLoS One. 2022 Jun 13;17(6):e0269641. doi: 10.1371/journal.pone.0269641. eCollection 2022.
8
Impact of non-invasive biomarkers on hepatology practice: Past, present and future.非侵入性生物标志物对肝脏病学实践的影响:过去、现在和未来。
J Hepatol. 2022 Jun;76(6):1362-1378. doi: 10.1016/j.jhep.2022.03.026.
9
Metabolic dysfunction and cancer in HCV: Shared pathways and mutual interactions.HCV 相关的代谢功能障碍与癌症:共同途径与相互作用。
J Hepatol. 2022 Jul;77(1):219-236. doi: 10.1016/j.jhep.2022.01.029. Epub 2022 Feb 12.
10
Kinetics of emergence of liver complications in hepatitis C virus infected patients and advanced fibrosis, with and without HIV-coinfection, after sustained virological response.慢性丙型肝炎病毒感染者在获得持续病毒学应答后发生肝脏并发症和肝纤维化进展的动力学:有无 HIV 合并感染的差异。
AIDS. 2021 Nov 1;35(13):2119-2127. doi: 10.1097/QAD.0000000000002959.